Why Your Bariatric Surgery Remains Effective Even After Weight Loss with GLP-1 Medications

More and more patients in Quebec are starting a weight loss medication, such as Wegovy, before undergoing bariatric surgery. These treatments are effective and well supported by scientific evidence, but they change the way weight loss unfolds after surgery¹.

In this article, we explain why patients using GLP-1 medications may experience what appears to be less dramatic postoperative weight loss — and why this still represents an excellent overall success.

Why Your Bariatric Surgery Remains Effective Even After Weight Loss with GLP-1 Medications

Why Weight Loss May Seem Less Significant After Surgery

If you have taken Wegovy, Ozempic, Mounjaro, or Zepbound before your surgery, you may feel that your weight loss after the procedure is less than expected.

This phenomenon is simple to explain: part of the work has already been done by the medication. The pounds lost with a GLP-1 are, in reality, pounds that the surgery would have also helped you lose. In other words, your body is already engaged in a weight loss process even before the procedure².

Let’s take a concrete example. A person who loses 40 lb with a GLP-1, then an additional 30 lb after a sleeve gastrectomy, achieves a total weight loss of 70 lb. This often corresponds to approximately 60% of excess weight loss, which is fully consistent with expected outcomes for bariatric surgery³.

So even if postoperative weight loss appears less impressive, the overall weight loss remains clinically significant.

Bariatric Surgery: A Tool to Stabilize Your Results

A key point to understand is that GLP-1 medications are effective as long as they are being taken. When they are stopped, the biological drivers of hunger return, and weight regain is common⁴.

To explore this further: When Weight‑Loss Medications Aren’t Enough: A Look at Long‑Term Solutions

Bariatric surgery works differently. It not only allows continued weight loss but, more importantly, helps consolidate existing results and maintain them over the long term. This is explained by durable changes in hunger hormones, satiety, and metabolism⁵.

In other words, surgery is not simply additional weight loss — it protects and stabilizes the progress already achieved with medication.

Understanding the Difference: The Portion Size Example

A simple way to understand this difference is to look at how portion sizes change over time. Before any treatment, a person may consume the equivalent of one to two full plates per meal.

With a medication like Wegovy, these portions generally decrease to about 1.5 to 2 cups per meal. After bariatric surgery, they often stabilize at around 1 cup per meal.

If portions have already been reduced by the medication, the transition after surgery may seem less dramatic. However, the restriction becomes more consistent and durable, which contributes to maintaining weight loss over the long term⁵.

Medications vs Surgery: What the Data Shows

Clinical studies show that GLP-1 medications lead to an average weight loss of 10–22% of total body weight¹⁶. In comparison, bariatric surgery typically results in a loss of approximately 50–70% of excess weight, depending on the procedure used³.

Even in the presence of significant preoperative weight loss, surgery continues to provide an additional and lasting benefit.

To learn more about overall benefits: Why Have Bariatric Surgery?

A Combined Approach Is Increasingly Used

In Quebec and elsewhere, it is increasingly common to combine medical and surgical approaches. Some patients use a GLP-1 before surgery to improve their health and reduce surgical risks. Others may resume or continue medication after surgery in cases of plateau or weight regain⁷.

This integrated approach maximizes results and increases the likelihood of long-term weight maintenance.

Sleeve Gastrectomy or Gastric Bypass: A Personalized Choice

Sleeve gastrectomy involves removing approximately 70–80% of the stomach, which leads to a significant reduction in hunger and a loss of about 50–60% of excess weight³.

Gastric bypass, on the other hand, combines a reduction in stomach size with a modification of the digestive tract. It allows for slightly greater weight loss — about 60–70% of excess weight — with a more significant metabolic impact, particularly on diabetes⁸.

The choice between these two options depends on your health, your goals, and your medical history. A personalized evaluation remains essential.

To understand eligibility: New Bariatric Surgery Eligibility Criteria

Conclusion: Key Takeaways

Patients who use GLP-1 medications before surgery may observe less dramatic postoperative weight loss, but this does not mean failure. On the contrary, the total combined weight loss remains excellent and often aligns with expected surgical outcomes³.

Bariatric surgery plays a key role in consolidating the results achieved with medication and in providing long-term control over hunger and portion sizes, which is difficult to maintain with pharmacological treatment alone⁵.

In many cases, combining both approaches leads to the best long-term results⁷.

To understand the next steps in the journey: Recovery and Life After Bariatric Surgery

To explore costs and options: How much does a Bariatric Surgery/Weight Loss Surgery Cost in Canada and what is included

Are You Taking a Weight Loss Medication and Considering Bariatric Surgery?

Every journey is unique. A medical evaluation can help determine the best strategy to maximize your results and ensure long-term weight maintenance.

Contact our team for a personalized evaluation at our private clinic in Quebec.

References

Wilding JPH et al. New England Journal of Medicine, 2021 (Semaglutide)
STEP Clinical Trial Program – GLP-1 weight loss data
American Society for Metabolic and Bariatric Surgery (ASMBS) – Outcomes of bariatric surgery
Rubino D et al. Diabetes, Obesity and Metabolism, 2021 – Weight regain after GLP-1 discontinuation
Mechanisms of bariatric surgery – Endocrine Reviews
Jastreboff AM et al. New England Journal of Medicine, 2022 (Tirzepatide, SURMOUNT-1)
Obesity Reviews – Combined medical and surgical obesity treatment
Schauer PR et al. New England Journal of Medicine – Bariatric surgery and metabolic outcomes